| 5 mins | 30 mins | Hourly | Daily | Weekly |
|---|---|---|---|---|
| BUY | BUY | BUY | SELL | SELL |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MA5 | 1.04▲ | 1.04▲ | 1.04▲ | 1.07▼ | 1.06▲ |
| MA10 | 1.04▲ | 1.04▲ | 1.04▲ | 1.05▲ | 1.19▼ |
| MA20 | 1.04▲ | 1.04▲ | 1.04▲ | 1.06▲ | 1.33▼ |
| MA50 | 1.04▲ | 1.08▲ | 1.10▼ | 1.22▼ | 1.83▼ |
| MA100 | 1.11▼ | 1.16▼ | 1.19▼ | 1.36▼ | 1.99▼ |
| MA200 | 1.19▼ | 1.28▼ | 1.31▼ | 1.73▼ | N/A |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MACD | 0.005▲ | 0.007▲ | 0.009▲ | 0.016▲ | -0.014▼ |
| RSI | 76.745▲ | 64.299▲ | 59.560▲ | 43.103▼ | 35.166▼ |
| STOCH | 33.333 | 27.778 | 38.611 | 68.249 | 9.084▼ |
| WILL %R | 0.000▲ | 0.000▲ | 0.000▲ | -42.500 | -83.571▼ |
| CCI | 375.078▲ | 278.287▲ | 245.098▲ | 109.917▲ | -87.994 |
|
Wednesday, October 21, 2026 04:30 AM
ImmunityBio, Inc. (NASDAQ: IBRX), an immunotherapy company, today announced completion of the database lock for Cohort A of QUILT-2.005 (NCT02138734), its randomized, controlled, registrational trial ...
|
|
Friday, October 16, 2026 09:20 AM
ImmunityBio has secured early FDA label expansion for Anktiva in BCG-unresponsive NMIBC. Check out why IBRX stock is a hold.
|
|
Thursday, September 03, 2026 07:54 AM
ImmunityBio looks attractive due to ANKTIVA's FDA approval for BCG-unresponsive NMIBC and pipeline expansion potential. See why I rate IBRX stock a Buy.
|
| date | open | high | low | close | volume |
|---|---|---|---|---|---|
| 23/10/26 | 1.0923 | 1.15 | 1.0415 | 1.065 | 5,838 |
| 22/10/26 | 1.12 | 1.12 | 1.07 | 1.09 | 5,729 |
| 21/10/26 | 1.12 | 1.13 | 1.08 | 1.08 | 10,966 |
| 20/10/26 | 1.03 | 1.08 | 1.03 | 1.08 | 3,248 |
| 19/10/26 | 1.02 | 1.065 | 1.02 | 1.04 | 39,689 |
| 16/10/26 | 1.0301 | 1.0301 | 1.02 | 1.02 | 5,409 |
| 15/10/26 | 1.015 | 1.035 | 1.015 | 1.03 | 4,503 |
| 14/10/26 | 1.00 | 1.02 | 0.9977 | 1.00 | 26,811 |
| 13/10/26 | 1.01 | 1.04 | 0.9999 | 1.02 | 10,157 |
| 12/10/26 | 1.03 | 1.035 | 1.01 | 1.03 | 18,909 |
|
|
||||
|
|
||||
|
|